Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2)
reduce the risk of a first hospitalization for heart failure, possibly through glucose-…

RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system
blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain…

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure and cardiovascular death among patients with chronic heart failure …

Background Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the
number of colorectal adenomas in animals and patients with familial adenomatous polyposis …

Objectives: Upon completing the reading of this article, the participants will better be able to:
1. Describe the conventional two-dimensional acoustic windows required for optimal …

Quantification of cardiac chamber size, ventricular mass, and function ranks among the
most clinically important and most frequently requested tasks of echocardiography. …

Background We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with
enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, …

Background This trial was designed to determine whether cardiac-resynchronization therapy
(CRT) with biventricular pacing would reduce the risk of death or heart-failure events in …

Background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce mortality
and cardiovascular morbidity among patients with myocardial infarction complicated by …

Background The presence of coexisting conditions has a substantial effect on the outcome of
acute myocardial infarction. Renal failure is associated with one of the highest risks, but the …